Difference between revisions of "Belinostat (Beleodaq)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "==Diseases for which it is established==" to "==Diseases for which it is established ''(work in progress)''==") |
m |
||
| Line 18: | Line 18: | ||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
| − | * | + | *2014-07-03: [http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm403929.htm FDA accelerated approval] for the treatment of patients with relapsed or refractory [[Peripheral_T-cell_lymphoma | peripheral T-cell lymphoma (PTCL)]]. ''(Based on BELIEF)'' |
==Also known as== | ==Also known as== | ||
Revision as of 14:02, 7 May 2023
General information
Class/mechanism: Histone deacetylase (HDAC) inhibitor. Belinostat causes cell cycle arrest and/or apoptosis of tumor cells by blocking HDAC, which results in accumulation of acetylated histones and other proteins.[1][2][3]
Route: IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is established (work in progress)
Diseases for which it is used
Patient drug information
- Belinostat (Beleodaq) package insert[1]
- Belinostat (Beleodaq) patient drug information (Chemocare)[4]
- Belinostat (Beleodaq) patient drug information (UpToDate)[5]
History of changes in FDA indication
- 2014-07-03: FDA accelerated approval for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). (Based on BELIEF)
Also known as
- Code name: PXD101
- Brand name: Beleodaq